Table 2

 Baseline clinical characterisation of patients who underwent serial echocardiography

FS at last evaluationp Value
>25%⩽25%
Data are mean (SD (range) or number (%).
Number of patients440 (95.2%)22 (4.8%)NA
Men/women278/16212/100.4
Age (years)41 (14) (16–79)41 (15) (19–71)0.8
Age at diagnosis (years)36 (15) (3–78)35 (17) (11–71)0.6
Follow up (months)64 (40) (12–192)100 (47) (16–193)0.007
VF9 (2.0%)1 (4.5%)NA
AF67 (15.2%)6 (27.3%)0.1
Exertional chest pain126 (28.6%)10 (45.5%)0.07
NYHA class
    I269 (61.0%)13 (59.1%)0.2
    II159 (36.1%)8 (36.4%)1
    III–IV13 (2.9%)1 (4.5%)NA
Family history of SCD134 (30.4%)8 (36.4%)0.5
Palpitations115 (26.1%)7 (31.8%)0.3
Syncope67 (15.2%)10 (45.5%)0.001
Abnormal BP response131 (29.7%)15 (68.2%)0.001
Non-sustained VT91 (20.6%)11 (50.0%)0.002
Severe LVH42 (9.6%)4 (18.2%)0.3
Risk factor SD
    0164 (37.2%)2 (9.1%)NA
    1165 (37.4%)8 (36.4%)NA
    289 (20.2%)6 (27.3%)NA
    321 (4.8%)4 (18.2%)NA
    41 (0.2%)2 (9.1%)NA
    51 (0.2%)0<0.0001
LVOTG108 (24.5%)3 (13.6%)0.3
Wigle4.4 (2.6) (0–10)5.5 (2.2) (0–10)0.09
MLVWT (mm)20.5 (6.1) (8–43)23.4 (6.0) (14–37)0.04
LVEDD (mm)43.6 (5.9) (28–60)48.3 (6.7) (39–65)0.0003
LVESD (mm)24.7 (5.4) (10–43)30.7 (6.5) (20–45)<0.0001
FS (%)43.3 (8.0) (26–72)36.7 (7.1) (27–48)0.0002
LA diameter (mm)42.9 (8.2) (20–72)45.8 (6.4) (34–57)0.1